About NXPE family member 1
NXPE family member 1 (NXPE1) is a protein
from Homo sapiens identified by UniProt accession
Q8N323, 547 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | NXPE family member 1 |
| UniProt accession | Q8N323 |
| Gene | NXPE1 |
| Organism | Homo sapiens |
| Length | 547 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- ulcerative colitis · score 0.42
- blood protein measurement · score 0.36
- inflammatory bowel disease · score 0.30
- protein measurement · score 0.29
- inflammatory skin disease · score 0.29
- Crohn's disease · score 0.28
- psoriasis · score 0.28
- ankylosing spondylitis · score 0.28
- sclerosing cholangitis · score 0.28
- actinic keratosis · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N323-F1 | alphafold | PREDICTED | 91.46 | — |
Amino-acid sequence (547 residues)
MSSNTMLQKT LLILISFSVV TWMIFIISQN FTKLWSALNL SISVHYWNNS AKSLFPKTSL IPLKPLTETE LRIKEIIEKL DQQIPPRPFT HVNTTTSATH STATILNPRD TYCRGDQLDI LLEVRDHLGQ RKQYGGDFLR ARMSSPALTA GASGKVMDFN NGTYLVSFTL FWEGQVSLSL LLIHPSEGAS ALWRARNQGY DKIIFKGKFV NGTSHVFTEC GLTLNSNAEL CEYLDDRDQE AFYCMKPQHM PCEALTYMTT RNREVSYLTD KENSLFHRSK VGVEMMKDRK HIDVTNCNKR EKIEETCQVG MKPPVPGGYT LQGKWITTFC NQVQLDTIKI NGCLKGKLIY LLGDSTLRQW IYYFPKVVKT LKFFDLHETG IFKKHLLLDA ERHTQIQWKK HSYPFVTFQL YSLIDHDYIP REIDRLSGDK NTAIVITFGQ HFRPFPIDIF IRRAIGVQKA IERLFLRSPA TKVIIKTENI REMHIETERF GDFHGYIHYL IMKDIFKDLN VGIIDAWDMT IAYGTDTIHP PDHVIGNQIN MFLNYIC
Explore NXPE family member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets